Zykadia Alternatives Compared
| Zykadia (ceritinib) | Opdivo (nivolumab) | Rybrevant (amivantamab) |
|
|---|
| Zykadia (ceritinib) | Opdivo (nivolumab) | Rybrevant (amivantamab) |
|
|||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Non Small Cell Lung Cancer. Zykadia may also be used for purposes not listed in this medication guide. |
Prescription only
Opdivo is an immune checkpoint inhibitor that may be used to treat many different cancers including melanoma, bladder cancer, liver cancer, and lung cancer. Fatigue, skin conditions, a cough, upper... View more |
Prescription only
Prescribed for Non Small Cell Lung Cancer. Rybrevant may also be used for purposes not listed in this medication guide. |
||||||||||||||||
| More about Zykadia (ceritinib) | More about Opdivo (nivolumab) | More about Rybrevant (amivantamab) | ||||||||||||||||
| Ratings & Reviews | ||||||||||||||||||
|
Be the first to share your experience with this drug. |
Opdivo has an average rating of 5.8 out of 10 from a total of 94 ratings on Drugs.com. 52% of reviewers reported a positive effect, while 40% reported a negative effect. |
Rybrevant has an average rating of 8.5 out of 10 from a total of 4 ratings on Drugs.com. 100% of reviewers reported a positive effect, while 0% reported a negative effect. |
||||||||||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | ||||||||||||||||||
|
View all Zykadia side effects |
View all Opdivo side effects |
View all Rybrevant side effects |
||||||||||||||||
| Drug Class | ||||||||||||||||||
| Generic Availability | ||||||||||||||||||
|
N/A |
N/A |
|||||||||||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||||||||||
|
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
View all Opdivo prices |
View all Rybrevant prices |
||||||||||||||||
| Dosage Forms | ||||||||||||||||||
|
|
|
||||||||||||||||
| Brand Names | ||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | ||||||||||||||||||
|
41 hours |
640.8 hours |
271.2 hours |
||||||||||||||||
| CSA Schedule 1 View glossary of CSA terms | ||||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||
| Pregnancy Category | ||||||||||||||||||
|
Category D
Positive evidence of risk
See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
||||||||||||||||
| Drug Interactions | ||||||||||||||||||
|
A total of 723 drugs are known to interact with Zykadia:
|
A total of 588 drugs are known to interact with Opdivo:
|
A total of 16 drugs are known to interact with Rybrevant:
|
||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||
| Disease Interactions | ||||||||||||||||||
| First Approval Date | ||||||||||||||||||
|
April 29, 2014 |
December 22, 2014 |
N/A |
||||||||||||||||
| WADA Class View classifications | ||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||
| More Information | ||||||||||||||||||
| Patient Resources | ||||||||||||||||||
| Professional Resources | ||||||||||||||||||
| Related Treatment Guide | ||||||||||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.